论文部分内容阅读
血管加压素的类似物精氨酸加压素(DDAVP)用于临床治疗中枢性尿崩症已经10余年了。作者首先发现了通过非肠道或鼻内给药,其抗利尿作用可以维持20小时。由于用鼻内用药使病人不尽满意,导致出现了舌下含服和鼻腔喷雾两种新的给药方法。但这些新剂型不能保证供应,因此,作者研究了口服DDAVP溶液和片剂对中枢性尿崩症的治疗效果。
Arginine vasopressin (DDAVP), an analog of vasopressin, has been used clinically for the treatment of central diabetes insipidus for more than 10 years. The authors first discovered that their anti-diuretic effect could be sustained for 20 hours by parenteral or intranasal administration. As a result of intranasal medication to make patients unsatisfactory, resulting in sublingual and nasal spray two new methods of administration. However, the availability of these new dosage forms is not guaranteed. Therefore, the authors investigated the therapeutic effect of oral DDAVP solutions and tablets on central diabetes insipidus.